Table 2.
Characteristics of patients with complicated chemotherapy-induced diarrhea who underwent capsule endoscopy
| No | Cancer | PS | Treatment | Cycle | Diarrhea grade | Complicating signs | Neutrophil count* | Wall thickening of small intestine | Schedule time** | Endoscopic findings | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Redness | Erosion | Ulcer | ||||||||||
| 1 | Gastric | 1 |
Capecitabine Cisplatin Trastuzumab |
1 | 2 | Cramping, sepsis | 4070 | + | 14 | + | + | – |
| 2 | Gastric | 1 |
Capecitabine Cisplatin Trastuzumab |
3 | 2 | sepsis | 5330 | + | 17 | + | + | – |
| 3 | Gastric | 1 |
S-1 Docetaxel Cislatin |
1 | 1 | Cramping, fever | 6600 | – | 19 | + | + | – |
| 4 | Gastric | 2 |
S-1 Oxaliplatin |
1 | 3 | Cramping fever | 3100 | N/A | 11 | + | + | – |
| 5 | Gastric | 1 |
S-1 Cisplatin |
1 | 1 | Decreased PS fever | 2650 | + | 2 | + | + | + |
| 6 | Gastric | 1 |
Capecitabine Oxaliplatin |
1 | 3 | Cramping fever | 4290 | – | 9 | + | – | – |
| 7 | Gastric | 1 | 5-FU | 4 | 3 | Cramping | 4520 | + | 8 | + | + | + |
| 8 | Gastric | 1 |
S-1 Oxaliplatin |
1 | 2 | Cramping | 3210 | – | 2 | – | – | – |
| 9 | Gastric | 1 |
S-1 Cisplatin |
5 | 3 | – | 6570 | – | 7 | + | – | – |
| 10 | Gastric | 0 | S-1 | 8 | 3 | Vomiting | 2880 | – | 5 | – | – | – |
| 11 | Colon | 2 |
5-FU Oxaliplatin |
1 | 1 | Cramping ileus | 2990 | + | 3 | + | + | – |
| 12 | Colon | 1 |
S-1 Irinotecan Bevacizumab |
1 | 2 | Cramping vomiting | 3490 | + | 13 | + | – | – |
| 13 | Colon | 1 |
Capecitabine Oxaliplatin |
1 | 3 | Cramping | 2170 | + | 21 | + | + | + |
PS performance status, 5-FU 5-fluorouracil, N/A not available
*cells/mm3, **Number of days after the end of chemotherapy courses and capsule endoscopy